Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Am J Obstet Gynecol. 2019 May 22;221(5):474.e1–474.e11. doi: 10.1016/j.ajog.2019.05.029

Table 3:

Utilization of assisted fertility services.

Patients Utilizing Assisted Fertility Services Patients Not Utilizing Assisted Fertility Services Total, n
Endometrial Cancer Hyperplasia with Atypia Endometrial Cancer Hyperplasia with Atypia
Entire cohort, n (%) 151 (3.8) 69 (1.7) 2986 (74.5) 801 (20) 4007
Patients who received progestin therapya, n (%) 79 (9.7) 48 (5.9) 439 (53.7) 252 (30.8) 818
Patients who received fertility-sparing treatmentb, n (%) 47 (11.2) 41 (9.7) 169 (40.1) 164 (39) 421
Patients who experienced any pregnancy, n (%) 35 (29.9) 28 (23.9) 27 (23.1) 27 (23.1) 117
Patients who experienced a live birth, n (%) 18 (29) 13 (21) 15 (24.2) 16 (25.8) 62
a

: Includes patients who receiving progestin therapy exclusively and those who also subsequently underwent hysterectomy.

b

: Includes patients who were only treated with progestin therapy. All values represent frequencies followed by row percentages in parenthesis, unless otherwise indicated.